Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory
Open Access
- 12 February 2021
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 9 (2), e001586
- https://doi.org/10.1136/jitc-2020-001586
Abstract
Background Human cancers are extraordinarily heterogeneous in terms of tumor antigen expression, immune infiltration and composition. A common feature, however, is the host′s inability to mount potent immune responses that prevent tumor growth effectively. Often, naturally primed CD8+ T cells against solid tumors lack adequate stimulation and efficient tumor tissue penetration due to an immune hostile tumor microenvironment. Methods To address these shortcomings, we cloned tumor-associated antigens (TAA) and the immune-stimulatory ligand 4-1BBL into the genome of modified vaccinia Ankara (MVA) for intratumoral virotherapy. Results Local treatment with MVA-TAA-4-1BBL resulted in control of established tumors. Intratumoral injection of MVA localized mainly to the tumor with minimal leakage to the tumor-draining lymph node. In situ infection by MVA-TAA-4-1BBL triggered profound changes in the tumor microenvironment, including the induction of multiple proinflammatory molecules and immunogenic cell death. These changes led to the reactivation and expansion of antigen-experienced, tumor-specific cytotoxic CD8+ T cells that were essential for the therapeutic antitumor effect. Strikingly, we report the induction of a systemic antitumor immune response including tumor antigen spread by local MVA-TAA-4-1BBL treatment which controlled tumor growth at distant, untreated lesions and protected against local and systemic tumor rechallenge. In all cases, 4-1BBL adjuvanted MVA was superior to MVA. Conclusion Intratumoral 4-1BBL-armed MVA immunotherapy induced a profound reactivation and expansion of potent tumor-specific CD8+ T cells as well as favorable proinflammatory changes in the tumor microenvironment, leading to elimination of tumors and protective immunological memory.Keywords
This publication has 60 references indexed in Scilit:
- Genetic Adjuvantation of Recombinant MVA with CD40L Potentiates CD8 T Cell Mediated ImmunityFrontiers in Immunology, 2013
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune EscapeCancer Research, 2012
- Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8 + T-cell immunityProceedings of the National Academy of Sciences of the United States of America, 2011
- Immune Requirements of Post-Exposure Immunization with Modified Vaccinia Ankara of Lethally Infected MicePLOS ONE, 2010
- Vaccinia Virus-Mediated Inhibition of Type I Interferon Responses Is a Multifactorial Process Involving the Soluble Type I Interferon Receptor B18 and Intracellular ComponentsJournal of Virology, 2009
- Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protectionJCI Insight, 2008
- Interleukin-15/Interleukin-15Rα Complexes Promote Destruction of Established Tumors by Reviving Tumor-Resident CD8+ T CellsCancer Research, 2008
- Age-dependent tolerance to an endogenous tumor-associated antigenVaccine, 2008
- Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cellsNature Immunology, 2003
- HIV-Specific Cd8+ T Cells Produce Antiviral Cytokines but Are Impaired in Cytolytic FunctionThe Journal of Experimental Medicine, 2000